SI-BONE reports record Q4 revenue $38.9M (+22% YoY); FY23 revenue $138.9M (+31%); issues FY24 guidance $162-165M

SI-BONE, Inc.

2023-FY EPS reported -$1.13 revenue$138,886,000

Q4 worldwide revenue $38.9M (+22% YoY); US revenue $36.7M (+22%); gross margin 74% (down from 84%) due to $1.7M excess inventory reserve.
FY23 worldwide revenue $138.9M (+31% YoY); US revenue $130.6M (+32%); net loss improved 29% to $43.3M; adjusted EBITDA loss improved 48% to $17.3M.
Over 1,600 US physicians performed >15,000 procedures in 2023; active physicians grew 22% to >1,130 in Q4.
FY24 guidance: revenue $162-165M (17-19% growth); gross margin ~78%; OpEx growth ~9%; expects significant adjusted EBITDA improvement.
Cash and equivalents ~$166M; net cash usage ~$0.8M in Q4.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

SI-BONE, Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 26, 2024, SI-BONE, Inc. (the "Company") issued a press release (the “Press Release”) announcing results for the quarter and year ended December 31, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

SI-BONE, Inc. filing history →

Source: SEC EDGAR

accession 0001459839-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.